Meeder Asset Management’s Cogent Biosciences COGT Stock Holding History

Meeder Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.75K	Sell	71 -69	-49%	-$2.41K	﹤0.01%	903
2026 Q1	$5.39K	Buy	+140	New	+$5.17K	﹤0.01%	809
2019 Q4	–	Sell	-1,142	Closed	-$7K	–	2273
2019 Q3	$7K	Buy	1,142 +1,000	+704%	+$8.13K	﹤0.01%	1637
2019 Q2	$1K	Buy	142 +71	+100%	+$945	﹤0.01%	1936
2019 Q1	$1K	Sell	71 -99	-58%	-$1.69K	﹤0.01%	1612
2018 Q4	$2K	Buy	170 +131	+336%	+$3.88K	﹤0.01%	1563
2018 Q3	$2K	Buy	+39	New	+$2.2K	﹤0.01%	1431

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Meeder Asset Management's COGT Position: Q2 2026 in Review

Meeder Asset Management reduced its Cogent Biosciences (COGT) stake by 49% in Q2 2026, selling an estimated $2.41K and leaving 71 shares worth $2.75K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Meeder Asset Management first reported a position in COGT in Q3 2018 and has held it in 7 quarters since. The position peaked at $7K in Q3 2019. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Meeder Asset Management held 71 shares of Cogent Biosciences worth $2.75K as of Q2 2026.
Meeder Asset Management sold 69 Cogent Biosciences shares in Q2 2026, an estimated $2.41K.
Cogent Biosciences made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #903 holding.
Meeder Asset Management first reported a position in Cogent Biosciences in Q3 2018 and has held it in 7 quarters since.
Meeder Asset Management's Cogent Biosciences position peaked at $7K in Q3 2019.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.